Pemetrexed (Alimta)
Novel and Future Treatment Options in Mesothelioma: A Systematic Review
International Journal of Molecular Sciences 2022 February 10 [Link] Danijela Štrbac, Vita Dolžan Abstract Mesothelioma is a rare tumor, frequently associated with asbestos exposure, arising from pleura and peritoneum. Traditionally, diagnosis and treatment have been difficult in a clinical setting. The treatment is based on a trimodal approach involving surgery, chemotherapy, and radiotherapy. The introduction…
Read MoreFirst-line nivolumab plus ipilimumab versus chemotherapy in patients with unresectable malignant pleural mesothelioma: 3-year outcomes from CheckMate 743
Annals of Oncology 2022 February 3 [Link] S Peters, A Scherpereel, R Cornelissen, Y Oulkhouir, L Greillier, M A Kaplan, T Talbot, I Monnet, S Hiret, P Baas, A K Nowak, N Fujimoto, A S Tsao, A S Mansfield, S Popat, X Zhang, N Hu, D Balli, T Spires, G Zalcman Abstract Background: In the…
Read MoreNew Era for Malignant Pleural Mesothelioma: Updates on Therapeutic Options
Journal of Clinical Oncology 2022 January 5 [Link] Anne S Tsao, Harvey I Pass, Andreas Rimner, Aaron S Mansfield Abstract Malignant pleural mesothelioma (MPM) is a rare malignancy with few treatment options. Recent advances have led to US Food and Drug Administration approvals and changes in the standard of care with a novel biomedical device…
Read MoreImmunotherapy, the promise for present and future of malignant pleural mesothelioma (MPM) treatment
Therapeutic Advances In Medical Oncology 2021 December 10 [Link] Valérie Gounant, Solenn Brosseau, Gérard Zalcman Abstract Due to occupational asbestosis exposure, the incidence of malignant pleural mesothelioma (MPM) has continuously increased over the last 30 years, with a plateau anticipated around the year 2030 in Western countries. Molecular MPM carcinogenesis involves alterations of NF2, RASSF1,…
Read MoreEGFR-targeted pemetrexed therapy of malignant pleural mesothelioma
Drug Delivery and Translational Research 2021 November 20 [Link] Liang Yang, Hanghang Fang, Jingjing Jiang, Yongjie Sha, Zhiyuan Zhong, Fenghua Meng Abstract Malignant pleural mesothelioma (MPM) is a rare malignancy with poor prognosis, for which chemotherapy with pemetrexed (PEM) is among the few clinical treatments. PEM suffers, however, fast clearance, moderate drug exposure, and dose-limiting…
Read MoreDurvalumab with platinum-pemetrexed for unresectable pleural mesothelioma: survival, genomic and immunologic analyses from the phase 2 PrE0505 trial
Nature Medicine 2021 November [Link] Patrick M Forde, Valsamo Anagnostou, Zhuoxin Sun, Suzanne E Dahlberg, Hedy L Kindler, Noushin Niknafs, Thomas Purcell, Rafael Santana-Davila, Arkadiusz Z Dudek, Hossein Borghaei, Mara Lanis, Zineb Belcaid, Kellie N Smith, Archana Balan, James R White, Christopher Cherry, I K Ashok Sivakumar, Xiaoshan M Shao, Hok Yee Chan, Dipika Singh,…
Read MoreHighly sensitive quantification of pemetrexed in human plasma using UPLC-MS/MS to support microdosing studies
Biomedical Chromatography 2021 November 5 [Link] Eleonora W J van Ewijk-Beneken Kolmer, Marga J A Teulen, Rene J Boosman, Nikki de Rouw, Jacobus A Burgers, Rob Ter Heine Abstract Pemetrexed is an antifolate drug approved for the treatment of non-small-cell lung cancer and mesothelioma. Assessing pemetrexed pharmacokinetics after administration of a microdose (100 μg) may…
Read MoreJME-001 phase II trial of first-line combination chemotherapy with cisplatin, pemetrexed, and nivolumab for unresectable malignant pleural mesothelioma
Journal for Immunotherapy of Cancer 2021 October [Link] Yosuke Miyamoto, Toshiyuki Kozuki, Keisuke Aoe, Sae Wada, Daijiro Harada, Michihiro Yoshida, Jun Sakurai, Katsuyuki Hotta, Nobukazu Fujimoto Abstract Background: JME-001 is a phase II trial assessing the efficacy and safety of cisplatin, pemetrexed, and nivolumab as first-line therapy in malignant pleural mesothelioma (MPM). Patients and methods:…
Read MoreTreatment patterns and outcomes in older patients with advanced malignant pleural mesothelioma: Analyses of Surveillance, Epidemiology, and End Results-Medicare data
Cancer Reports 2021 October 26 [Link] Mark D Danese, Melinda Daumont, Esmond Nwokeji, Michelle Gleeson, John R Penrod, Deborah Lubeck Abstract Background: Malignant mesothelioma is a rare neoplasm associated with asbestos exposure. Characterizing treatment patterns and outcomes of older patients with advanced malignant pleural mesothelioma (MPM) is important to understand the unmet needs of this…
Read MoreQuinacrine Has Preferential Anticancer Effects on Mesothelioma Cells With Inactivating NF2 Mutations
Frontiers in Pharmacology 2021 September [Link] Derek B Oien, Sayantani Sarkar Bhattacharya, Jeremy Chien, Julian Molina, Viji Shridhar Abstract Mesothelioma is a rare cancer with disproportionately higher death rates for shipping and mining populations. These patients have few treatment options, which can be partially attributed to limited chemotherapy responses for tumors. We initially hypothesized that…
Read More